Herman G.M. Westenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Herman G.M. Westenberg has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Harold J. G. M. van Megen
Department of Psychiatry, University Hospital Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands, Fax: +31-30-2505443
1 shared publicationJohan A. Den Boer
Department of Psychiatry, University Hospital Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands, Fax: +31-30-2505443
1 shared publicationKamini L. Ho Pian
Department of Psychiatry, University Hospital Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands, Fax: +31-30-2505443
1 shared publication
Latest Publications
- 1 December 1998
- Published by Springer Nature in Psychopharmacology
- Vol. 140 (3) , 365-370
Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder
The non-selective serotonin (5-HT) receptor agonist meta-chlorophenylpiperazine (mCPP) has been reported to elicit symptoms in patients with obsessive compulsive disorder (OCD). MK-212, another non-selective 5-HT receptor agonist, does not seem to induce obsessive compulsive symptoms in OCD patients. The major pharmacological difference between mCPP and MK-212 is their affinity for the 5-HTID receptor. The aim of this study was to explore the role of the 5-HTID receptor in the pathophysiology of OCD, by using a challenge paradigm with the selective 5-HTID receptor agonist sumatriptan (Imigran®). A randomized, double-blind, placebo-controlled cross-over challenge with sumatriptan (100 mg PO) was performed in 15 OCD patients. Neither the obsessive compulsive symptoms nor mood or anxiety symptoms changed significantly following sumatriptan administration as compared to placebo. Sumatriptan did induce a significant increase in plasma growth hormone (GH) levels. In the present study, no indication were found for the role of the 5-HTID receptor in the pathophysiology of OCD. It should be noted, however, that sumatriptan does not readily pass the blood-brain barrier. Selective 5-HTID receptors with better brain penetrating properties may shed more light on the role of this 5-HT receptor subtype in OCD.
- 1 December 1998
- Published by Springer Nature in Psychopharmacology
- Vol. 140 (3) , 365-370
Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder
The non-selective serotonin (5-HT) receptor agonist meta-chlorophenylpiperazine (mCPP) has been reported to elicit symptoms in patients with obsessive compulsive disorder (OCD). MK-212, another non-selective 5-HT receptor agonist, does not seem to induce obsessive compulsive symptoms in OCD patients. The major pharmacological difference between mCPP and MK-212 is their affinity for the 5-HTID receptor. The aim of this study was to explore the role of the 5-HTID receptor in the pathophysiology of OCD, by using a challenge paradigm with the selective 5-HTID receptor agonist sumatriptan (Imigran®). A randomized, double-blind, placebo-controlled cross-over challenge with sumatriptan (100 mg PO) was performed in 15 OCD patients. Neither the obsessive compulsive symptoms nor mood or anxiety symptoms changed significantly following sumatriptan administration as compared to placebo. Sumatriptan did induce a significant increase in plasma growth hormone (GH) levels. In the present study, no indication were found for the role of the 5-HTID receptor in the pathophysiology of OCD. It should be noted, however, that sumatriptan does not readily pass the blood-brain barrier. Selective 5-HTID receptors with better brain penetrating properties may shed more light on the role of this 5-HT receptor subtype in OCD.
- 1 September 1996
- Published by Elsevier in Journal of Affective Disorders
- Vol. 40 (1-2) , 85-93
Developments in the drug treatment of panic disorder: What is the place of the selective serotonin reuptake inhibitors?
- 1 September 1996
- Published by Elsevier in Journal of Affective Disorders
- Vol. 40 (1-2) , 85-93
Developments in the drug treatment of panic disorder: What is the place of the selective serotonin reuptake inhibitors?